Impact of mitral regurgitation on clinical outcomes of patients with low-ejection fraction, low-gradient severe aortic stenosis undergoing transcatheter aortic valve implantation. by O'Sullivan, Crochan J et al.
1The combination of a low left ventricular ejection frac-tion (LVEF) with a tight aortic orifice is frequently 
associated with a low transvalvular pressure gradient among 
patients with severe aortic stenosis (AS).1–9 Low-ejection frac-
tion, low-gradient severe AS (LEF-LG), represents a man-
agement challenge because of the high perioperative risk 
associated with conventional surgical aortic valve replace-
ment (SAVR).1,2,6,10,11 Transcatheter aortic valve implantation 
(TAVI) is a less invasive alternative procedure to SAVR for the 
treatment of high-risk patients presenting with symptomatic 
severe AS.12,13 Several studies have demonstrated the feasibil-
ity of TAVI to treat patients with symptomatic LEF-LG severe 
AS,7,9,14–17 which is reflected in the recent 2014 American Heart 
Association/American College of Cardiology guidelines pro-
viding a class IIa recommendation for TAVI for the treatment 
of symptomatic LEF-LG in high-risk patients.18
LEF-LG is present in ≈5% to 10% of the overall popula-
tion of patients with severe AS.6 However, the prevalence of 
LEF-LG among patients undergoing TAVI is higher (10% to 
16%) because of the predominance of high-risk patients.7,9,14,15 
Moderate to severe mitral regurgitation (MR) is present in 2% 
to 22% of unselected patients undergoing TAVI,19–22 whereas 
its prevalence in LEF-LG patients undergoing TAVI is consid-
erably higher (20% to 55%).7,9,14,15 Recently, several conflicting 
Background—Up to 1 in 6 patients undergoing transcatheter aortic valve implantation (TAVI) present with low-ejection 
fraction, low-gradient (LEF-LG) severe aortic stenosis and concomitant relevant mitral regurgitation (MR) is present in 
30% to 55% of these patients. The effect of MR on clinical outcomes of LEF-LG patients undergoing TAVI is unknown.
Methods and Results—Of 606 consecutive patients undergoing TAVI, 113 (18.7%) patients with LEF-LG severe aortic 
stenosis (mean gradient ≤40 mm Hg, aortic valve area <1.0 cm2, left ventricular ejection fraction <50%) were analyzed. 
LEF-LG patients were dichotomized into ≤mild MR (n=52) and ≥moderate MR (n=61). Primary end point was all-cause 
mortality at 1 year. No differences in mortality were observed at 30 days (P=0.76). At 1 year, LEF-LG patients with 
≥moderate MR had an adjusted 3-fold higher rate of all-cause mortality (11.5% versus 38.1%; adjusted hazard ratio, 
3.27 [95% confidence interval, 1.31–8.15]; P=0.011), as compared with LEF-LG patients with ≤mild MR. Mortality 
was mainly driven by cardiac death (adjusted hazard ratio, 4.62; P=0.005). As compared with LEF-LG patients with 
≥moderate MR assigned to medical therapy, LEF-LG patients with ≥moderate MR undergoing TAVI had significantly 
lower all-cause mortality (hazard ratio, 0.38; 95% confidence interval, 0.019–0.75) at 1 year.
Conclusions—Moderate or severe MR is a strong independent predictor of late mortality in LEF-LG patients undergoing TAVI. 
However, LEF-LG patients assigned to medical therapy have a dismal prognosis independent of MR severity suggesting that 
TAVI should not be withheld from symptomatic patients with LEF-LG severe aortic stenosis even in the presence of moderate 
or severe MR.  (Circ Cardiovasc Interv. 2015;8:e001895. DOI: 10.1161/CIRCINTERVENTIONS.114.001895.)
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studies reporting the effect of MR on clinical outcomes among 
unselected patients undergoing TAVI have emerged.23–29 
However, to date, no data exist on whether MR affects clinical 
outcomes among selective patients with LEF-LG undergoing 
TAVI. Therefore, the primary aim of this study was to assess 
the association of MR with clinical outcomes among this 
high-risk–selected patient population undergoing TAVI. The 
secondary aim was to compare clinical outcomes of LEF-LG 
patients assigned to TAVI versus a control medical therapy 
(MT) group stratified according to MR grade.
Methods
Patient Population
Since 2007, patients with severe AS and increased surgical risk un-
derwent a multidisciplinary assessment and were assigned to 1 of 
3 treatment modalities that is, MT, conventional SAVR, or TAVI. 
During the period between August 2007 and December 2012, 606 
patients were assigned to TAVI and 110 patients were assigned to 
MT.30 One hundred thirteen consecutive patients with symptomatic, 
severe LEF-LG native valve AS undergoing TAVI were included in 
this study (n=113/606; 18.6%; aortic valve area <1.0 cm2, mean gra-
dient ≤40 mm Hg, and LVEF <50%). Of the 110 consecutive patients 
assigned to MT, 44 patients had symptomatic LEF-LG severe AS, 
as previously described.30 Included patients with LEF-LG severe AS 
were dichotomized based on the presence of mild or less MR or mod-
erate or severe MR at baseline echocardiographic examination. This 
study complies with the Declaration of Helsinki, was approved by the 
local ethics committee, and all patients provided informed written 
consent.
Echocardiography
Transthoracic echocardiography was performed in all included pa-
tients at baseline as described in detail in the Data Supplement.
Dobutamine Stress Echocardiography
Dobutamine stress echocardiography was performed in one third of 
TAVI patients (n=36/113 [32%]) and in 5/39 (13%) MT patients as 
described in the Data Supplement.
Cardiac Catheterization
All TAVI patients underwent coronary angiography and 89 of 113 
(79%) TAVI patients had a full invasive hemodynamic evaluation 
by right and left heart catheterization before TAVI as previously de-
scribed.9 Twenty-nine of thirty-nine patients assigned to MT under-
went coronary angiography of which 27 patients had a simultaneous 
right heart catheterization. Pulmonary hypertension was defined as 
an invasive mean PA pressure >25 mm Hg and was dichotomized 
into precapillary (left ventricular end-diastolic pressure ≤15 mm Hg) 
and postcapillary (left ventricular end-diastolic pressure >15 mm Hg) 
subgroups.
Transcatheter Aortic Valve Implantation
TAVI was performed as previously described.31 Vascular access 
was transfemoral using the Edwards Sapien/XT valve (Edwards 
Lifesciences, Irvine, CA) or the Medtronic CoreValve Revalveing 
System (Medtronic Inc, Minneapolis, MN, transapical for the 
Edwards Sapien/XT valve or self-expanding Symetis Acurate 
TA valve (Symetis Inc, Switzerland) or transsubclavian using the 
Medtronic CoreValve Revalveing System.
Clinical Follow-Up
Adverse events were assessed in hospital, and regular clinical follow-
up was performed at 1, 6, and 12 months by means of a clinical visit 
or standardized telephone interview. All suspected events were adju-
dicated by an unblinded clinical event committee. Baseline clinical 
and procedural characteristics and all follow-up data were entered 
into a dedicated database, held at an academic clinical trials unit 
(CTU Bern, Bern University Hospital, Switzerland) responsible for 
central data audits and maintenance of the database.
Study End Points
Clinical end points were defined according to the criteria pro-
posed by the Valve Academic Research Consortium-2 consensus 
document.32 Primary end point was all-cause mortality at 1 year. 
Secondary end points included all-cause mortality at 30 days and 
cardiovascular death, and major adverse cardiovascular and cere-
brovascular events (composite of all-cause mortality, major stroke, 
and myocardial infarction) at 30 days and 1 year. New York Heart 
Association (NYHA) functional class status was assessed at base-
line and 1-year follow-up. Transthoracic echocardiography was 
performed during follow-up. Transthoracic echocardiography per-
formed on patients who survived to discharge and 1 year, respec-
tively, are included in this analysis.
Statistics
Continuous data are presented as mean±SD, and categorical vari-
ables are depicted as percentages and numbers. Categorical vari-
ables were compared by means of the χ2 test (or Fisher test for 
2 group comparisons), and continuous variables were compared 
using the unpaired t test. NYHA functional status at 1 year was 
WHAT IS KNOWN
s฀Low-ejection fraction, low-gradient (LEF-LG) se-
vere aortic stenosis is associated with a high peri-
operative mortality after conventional surgical aortic 
valve replacement but is associated with a dismal 
prognosis with conservative management.
s฀Evidence, to date, on the effect of mitral regurgita-
tion (MR) on clinical outcomes of unselected pa-
tients after transcatheter aortic valve implantation 
has been conflicting.
s฀Transcatheter aortic valve implantation has been 
shown to be a viable alternative to conventional 
surgical aortic valve replacement for the treatment 
of patients with LEF-LG severe aortic stenosis, al-
though overall and cardiovascular mortality rates re-
main stubbornly high.
WHAT THE STUDY ADDS
s฀Despite a similar baseline risk profile, LEF-LG pa-
tients with ≥moderate MR had an adjusted 3-fold 
higher rate of overall mortality at 1 year as compared 
with similar patients with mild or less MR.
s฀Among patients with ≥moderate MR, those with de-
generative MR had the worst prognosis.
s฀When compared with unmatched control LEF-LG 
severe aortic stenosis patients with ≥moderate MR 
assigned to medical therapy during the same treat-
ment period, LEF-LG severe aortic stenosis patients 
with ≥moderate MR undergoing transcatheter aortic 
valve implantation had significantly better outcomes 
suggesting that transcatheter aortic valve implanta-
tion should not be withheld from such patients.
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analyzed using χ2 tests. Time-to-event data are presented using 
Kaplan–Meier curves, with incidence rates calculated from life-ta-
bles, at 30 days and 1-year follow-up, respectively, for patients un-
dergoing TAVI and 1-year follow-up for comparisons between MT 
and TAVI patients. Univariate and adjusted Cox proportional haz-
ard models were used to derive hazard ratio (HR) estimates of clin-
ical time-to-event comparisons between the 2 groups. Twenty-three 
baseline variables were added into the univariate model. In the ad-
justed Cox models, only peripheral vascular disease (P=0.003) and 
the logistic EuroSCORE (P<0.001) were added because these were 
the only 2 factors with a P<0.1 affecting major adverse cardio-
vascular and cerebrovascular events. Baseline, discharge to 1-year 
follow-up changes in echocardiographic parameters were analyzed 
using linear mixed models with a random effect of the patient iden-
tifier to account for repeated measures per patient. Only survivors 
at discharge or at 1-year follow-up, respectively, were included in 
these repeated measures analyses. All P values and 95% confidence 
intervals (CIs) are 2-sided. Two-sided P<0.05 were considered 
Table 1. Baseline Characteristics
TAVI Patients
P Value
Mild or Less MR Moderate or Severe MR
n=52 n=61
Age, y 82.2±4.9 82.0±5.2 0.81
Women, n (%) 14 (26.9) 32 (52.5) 0.010
Height, cm 167.2±7.0 164.0±8.4 0.031
Weight, kg 73.5±13.9 66.2±13.9 0.006
Body mass index, kg/m2 26.3±4.5 24.6±5.0 0.06
Body surface area, m2 1.8±0.2 1.71±0.2 0.003
Cardiac risk factors
  Diabetes mellitus, n (%) 18 (34.6) 21 (34.4) 0.98
  Hypercholesterolemia, n (%) 39 (75.0) 37 (60.7) 0.11
  Hypertension, n (%) 44 (84.6) 47 (77.0) 0.31
  Current smoker, n (%) 7 (13.5) 6 (9.8) 0.55
Past medical history
  Previous stroke, n (%) 6 (11.5) 7 (11.5) 0.99
  Peripheral vascular disease, n (%) 11 (21.2) 20 (32.8) 0.24
  Chronic obstructive pulmonary disease, n (%) 10 (19.6) 8 (13.1) 0.35
  Renal failure (GFR<50 mL/min per 1.73 m2) 14 (26.9) 25 (41.0) 0.12
  Previous permanent pacemaker, n (%) 6 (11.5) 8 (13.1) 0.80
  Coronary artery disease, n (%) 37 (71.2) 47 (77.0) 0.62
  Previous MI, n (%) 15 (28.8) 16 (26.2) 0.92
  Previous CABG, n (%) 13 (25.0) 17 (27.9) 0.90
  Previous PCI, n (%) 22 (42.3) 22 (36.1) 0.50
  Atrial fibrillation, n (%) 11 (21.6) 15 (25.0) 0.67
Symptoms
  New York Heart Association (NYHA) Functional Class
   NYHA III/IV, n (%) 37 (71.2) 51 (83.6) 0.11
  CCS angina status
   CCS III/IV, n (%) 9 (17.3) 7 (11.5) 0.38
Risk assessment
  Logistic EuroScore, % 32.9±14.1 35.5±16.4 0.37
  STS score, % 7.1±4.4 8.67±5.0 0.08
Medications at baseline
  Diuretic, n (%) 35 (67.3) 50 (82.0) 0.07
  β-blocker, n (%) 30 (57.7) 39 (63.9) 0.50
  ACEi/ARB, n (%) 29 (55.8) 38 (62.3) 0.48
  Statin, n (%) 31 (59.6) 30 (49.2) 0.27
Laboratory values
  B-type natriuretic peptide, pg/mL 1065±943 1164±1078 0.69
Values are n (%) or mean±SD with P values from unpaired t tests or counts (%) with P values from χ2 tests. ACEi indicates angiotensin-converting 
enzyme inhibitors; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; MR, mitral 
regurgitation; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and TAVI, transcatheter aortic valve implantation.
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Table 2. Baseline Echocardiographic Characteristics
TAVI Patients
P Value
Mild or Less MR Moderate or Severe MR
n=52 n=61
Aortic stenosis severity
  Aortic valve area, cm2 0.74±0.23 0.73±0.200 0.93
  Indexed aortic valve area, cm2/m2 0.41±0.12 0.43±0.12 0.30
  Aortic maximal velocity, cm/s 3.3±0.7 3.2±0.5 0.30
  Mean gradient, mm Hg 29.6±10.1 27.5±10.5 0.29
  Peak gradient, mm Hg 47.3±16.5 45.8±15.6 0.65
LV geometry and two-dimensional measurements
  Interventricular septum in diastole, cm 1.4±0.3 1.2±0.3 0.024
  Posterior wall thickness in diastole, cm 1.4±0.9 1.1±0.2 0.11
  LV end-systolic diameter, cm 4.4±0.9 4.5±1.3 0.58
  LV end-diastolic diameter, cm 5.6±9.1 5.5±1.2 0.44
  Relative wall thickness 0.5±0.4 0.5±0.4 0.72
  LV mass index, g/m2 161.6±39.2 158.6±33.5 0.74
  Normal geometry, n (%) 1 (3.8) 2 (6.5) 0.51
  Concentric hypertrophy, n (%) 10 (38.5) 16 (51.6) 0.51
  Eccentric hypertrophy, n (%) 12 (46.2) 12 (38.7) 0.51
  Concentric remodeling, n (%) 3 (11.5) 1 (3.2) 0.51
LV systolic function
  LV ejection fraction, % 36.1±9.7 32.7±12.4 0.11
  LVOT diameter, mm 21.4±2.0 20.3±2.7 0.14
  Stroke volume, mL 59.7±18.1 48.8±17.2 0.057
  Stroke volume index, mL/m2 33.4±10.8 28.7±9.7 0.16
LV diastolic function
  E/A ratio 1.7±1.3 2.1±0.9 0.25
  Deceleration time, ms 199.2±79.2 144.7±27.4 0.009
  Isovolumic relaxation time, ms 80.5±31.4 80.9±38.4 0.99
  Left atrial diameter, mm 48.3±7.1 50.1±5.1 0.26
RV systolic function
  Tricuspid annular plane systolic excursion, cm 1.4±0.4 1.5±0.5 0.60
  Pulse doppler peak velocity at the annulus, cm/s 9.5±3.0 9.5±3.0 0.99
RV dimensions
  RV dilatation, n (%) 9 (19.1) 11 (21.2) 0.80
Associated valvular abnormality
  Aortic regurgitation 0.50
  None/trivial, n (%) 12 (25.0) 17 (30.9)
  Mild, n (%) 33 (68.8) 32 (58.2)
  Moderate, n (%) 3 (6.3) 6 (10.9)
  Severe, n (%) 0 (0) 0 (0)
  MR <0.0001
  None/trivial, n (%) 2 (3.8) 0 (0)
  Mild, n (%) 50 (96.2) 0 (0)
  Moderate, n (%) 0 (0) 58 (95.1)
  Severe, n (%) 0 (0) 3 (4.9)
 EROA, mm2 12.50±5.96 24.67±19.80
  Regurgitant volume, mL 16.25±4.03 41.14±32.05
  Tricuspid regurgitation <0.0001
  None/trivial, n (%) 9 (17.3) 2 (3.3)
  Mild, n (%) 37 (71.2) 30 (49.2)
  Moderate, n (%) 5 (9.6) 24 (39.3)
  Severe, n (%) 1 (1.9) 5 (8.2)
Right-sided hemodynamics
  RV/RA gradient, mm Hg 39.9±11.6 43.5±12.1 0.20
  Pulmonary artery systolic pressure, mm Hg 50.2±13.8 53.6±13.9 0.27
Values are n (%) or mean±SD. EROA indicates effective regurgitant orifice area; LV, left ventricle; LVOT, left ventricular outflow tract; MR, mitral 
regurgitation; RA, right atrium; RV, right ventricle; and TAVI, transcatheter aortic valve implantation.
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statistically significant. All analyses were performed with STATA 
(version 12, StataCorp, College Station, TX).
Results
Of the 113 patients with LEF-LG severe AS undergoing TAVI 
in this study, 52 patients had mild or less MR and 61 patients 
had moderate or severe MR (58 moderate and 3 severe MR). 
Of 44 patients with LEF-LG assigned to MT, 5 were excluded 
(3 missing MR grade and 2 crossed over to TAVI during 
inclusion period and were included in the TAVI group). Of 
the 39 remaining MT patients, 19 had mild or less MR and 20 
had moderate or severe MR. Baseline characteristics of TAVI 
patients stratified by MR grade are given in Table 1. Mean age 
was 82.1±5.0 years and there were significantly more women 
in the moderate or severe MR group. As a result, patients in 
the latter group were smaller and weighed less. No significant 
Table 3. Invasive Hemodynamic Characteristics
TAVI Patients
P Value
Mild or Less MR Moderate or Severe MR
n=43 n=46
Aortic stenosis severity
  Aortic valve area, cm2 0.69±0.25 0.66±0.33 0.63
  Indexed aortic valve area, cm2/m2 0.38±0.15 0.38±0.20 0.96
  Peak-to-peak gradient, mm Hg 31.5±22.2 31.4±20.0 0.98
  Mean gradient, mm Hg 26.2±7.8 25.3±9.3 0.61
  Stroke work loss, % 17.4±5.6 17.4±6.2 0.96
  Systolic ejection period, s/min 23.37±5.3 23.8±4.6 0.67
  Valvular resistance, dyne s/cm5 183.7±93.8 232.5±129.5 0.048
Systemic vascular load
  Systolic arterial pressure, mm Hg 127.4±26.3 124.2±23.9 0.56
  Diastolic arterial pressure, mm Hg 66.8±14.0 65.9±14.6 0.77
  Mean arterial pressure, mm Hg 91.7±17.7 89.5±14.7 0.53
  Systemic vascular resistance, mm Hg min/L 1973±643 2222±798 0.11
  Systemic arterial compliance, mL/mm Hg 0.50±0.27 0.42±0.22 0.12
LV global afterload
  Valvuloarterial Impedance, mm Hg/mL per m2 6.3±2.3 7.6±2.5 0.016
LV systolic function
  Ejection fraction,* % 33.7±8.7 30.7±8.2 0.10
  LV systolic pressure, mm Hg 158.7±26.0 153.5±22.8 0.32
  LV end-diastolic pressure, mm Hg 22.0±8.0 21.9±7.8 0.97
  LV stroke work, g/m 78.4±25.2 59.2±19.9 <0.001
  Stroke volume, mL 48.9±13.4 38.5±12.6 <0.001
  Stroke volume index, mL/m2 27.1±6.9 22.0±6.6 0.001
  Cardiac output, L/min 3.7±1.1 3.1±0.9 0.013
  Cardiac index, L/min per m2 2.0±0.5 1.8±0.4 0.021
  Heart rate, bpm−1 75.1±11.9 84.3±18.6 0.008
Right-sided hemodynamics
  PA systolic pressure, mm Hg 54.1±15.6 62.5±12.9 0.009
  Mean PA pressure, mm Hg 36.4±11.4 40.7±8.4 0.050
  Pulmonary hypertension, n (%) 31 (72.1) 43 (93.5) 0.010
  Precapillary PH, n (%) 3 (7.0) 9 (19.6) 0.013
  Postcapillary PH, n (%) 28 (65.1) 34 (73.9)
  RA mean pressure, mm Hg 9.2±5.6 9.9±5.9 0.59
Components of Fick equation
  Aortic saturation, % 94.4±2.3 94.7±2.9 0.63
  Pulmonary artery saturation, % 58.8±7.6 55.0±9.1 0.038
  Hemoglobin, g/dL 12.7±1.8 12.1±1.6 0.11
Values are n (%) or mean±SD. Pulmonary hypertension defined as a mean PA pressure ≥25 mm Hg. LV indicates left ventricle; MR, 
mitral regurgitation; PA, pulmonary artery; PH, pulmonary hypertension; RA, right atrium; and TAVI, transcatheter aortic valve implantation.
*Angiographic ejection fraction.
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differences in other baseline characteristics, including surgi-
cal risk scores, were observed between TAVI groups.
As compared with LEF-LG patients assigned to MT, patients 
undergoing TAVI had a lower prevalence of renal failure and 
atrial fibrillation, a higher prevalence of previous percutane-
ous coronary intervention and had lower surgical risk scores 
(Logistic EuroSCORE: 42.8±15.8% versus 34.3±15.4%; 
P=0.004; STS score: 11.3±7.2% versus 7.9±4.8%; P=0.001; 
Table I in the Data Supplement).
Baseline Echocardiographic Characteristics
Echocardiographic characteristics of TAVI patients 
stratified according to MR grade are presented in Table 2. 
No significant differences in baseline aortic valve 
Table 4. Procedural Characteristics
TAVI Patients
P Value
Mild or Less MR Moderate or Severe MR
n=52 n=61
General anesthesia, n (%) 23 (44.2) 23 (37.7) 0.48
Procedural duration, min 67±29 66±45 0.9
Aortic valve intervention
  Balloon predilation, n (%) 45 (86.5) 58 (95.1) 0.21
  Medtronic CoreValve, n (%) 32 (49.2) 33 (54.1) 0.54
  Edwards Sapien valve, n (%) 19 (36.5) 27 (44.3) 0.52
  Symetis valve, n (%) 1 (1.9) 1 (1.6) 0.91
Vascular access
  Transfemoral, n (%) 38 (73.1) 47 (77.0) 0.79
  Transapical, n (%) 11 (21.2) 12 (19.7)
  Transsubclavian, n (%) 3 (5.8) 2 (3.3)
Revascularization, n (%) 18 (34.6) 22 (36.1) 0.87
  Complete revascularization, n (%) 7 (13.5) 2 (3.3) 0.044
Vessels treated
  LM, n (%) 1 (2.5) 4 (10.0) 0.47
  LAD, n (%) 12 (30.0) 11 (27.5) 0.46
  LCX, n (%) 3 (7.7) 4 (10.3) 0.97
  RCA, n (%) 9 (22.5) 3 (7.5) 0.032
  Vein graft, n (%) 1 (2.7) 3 (8.1) 0.81
  Concomitant PCI, n (%) 6 (11.5) 10 (16.4) 0.46
  Staged PCI, n (%) 12 (23.1) 12 (19.7) 0.66
  Hospital stay, d 7.7±3.3 8.0±7.1 0.74
  Conversion to SAVR, n (%) 0 (0) 1 (1.6) 0.54
  Postprocedural aortic regurgitation ≥2+, n (%) 10 (19.2) 9 (14.8) 0.37
Values are n (%) or mean±SD. LAD indicates left anterior descending; LCX, left circumflex; LM, left main stem; MR, mitral 
regurgitation; PCI, percutaneous coronary intervention; RCA, right coronary artery; SAVR, surgical aortic valve replacement; and TAVI, 
transcatheter aortic valve implantation.
Figure 1. Kaplan–Meier analysis of death (A) and cardiovascular death (B) at 1 year among patients with low-ejection fraction, low-gra-
dient severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) stratified according to the presence of mild or less 
mitral regurgitation (MR) and moderate or severe MR at baseline.
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area, mean gradient, LVEF, or right ventricular ejection 
fraction were observed. TAVI patients with moderate to severe 
MR had significantly worse diastolic function as compared 
with mild or less MR TAVI patients. Among TAVI patients 
with moderate to severe MR, MR was classified as functional 
in 44 of 61 (72%) and degenerative in 17 of 61 (28%).
Contractile reserve was present in 11 of 17 (64.7%) of 
mild or less MR TAVI patients and 16 of 19 (84.2%) of TAVI 
patients with moderate or severe MR (P=0.18). Baseline 
mean gradient was significantly lower among the moderate to 
severe MR group (23.4±6.2 mm Hg versus 18.7±7.1 mm Hg; 
P=0.049) but mean gradients reached at peak dobutamine 
infusion were similar (37.2±7.3 mm Hg versus 32.0±10.7 
mm Hg; P=0.10). Aortic valve area remained fixed at peak 
dobutamine infusion in patients with both mild or less MR 
(aortic valve area baseline versus peak dobutamine infusion: 
0.78±0.28 mm Hg versus 0.81±0.34 mm Hg) and moderate or 
severe MR (0.80±0.23 mm Hg versus 0.83±0.25 mm Hg).
As compared with LEF-LG patients assigned to MT, 
patients assigned to TAVI had a higher baseline LVEF 
(29.3±9.6% versus 34.4±11.2%; P=0.014; Table II in the 
Data Supplement).
Baseline Invasive Hemodynamic Characteristics
Invasive hemodynamic characteristics of TAVI patients strati-
fied according to MR severity are presented in Table 3. As com-
pared with mild or less MR TAVI patients, moderate or severe 
MR TAVI patients had significantly higher valvular resistances 
and valvuloarterial impedances. In addition, moderate or 
severe MR TAVI patients had significantly higher pulmonary 
artery pressures (mean and systolic) and a higher incidence of 
pulmonary hypertension as compared with mild or less MR 
patients. Pulmonary hypertension was predominantly postcap-
illary in both the TAVI groups. TAVI patients with moderate to 
severe MR had a significantly lower stroke volume and cardiac 
output as compared with TAVI patients with mild or less MR.
As compared with LEF-LG patients assigned to MT, 
patients undergoing TAVI had somewhat higher stroke volume 
indices (21.0±5.1 mL/m2 versus 24.5±7.2 mL/m2; P=0.021) 
and lower heart rates (86.8±12.2 bpm versus 79.7±16.4 bpm; 
P=0.041; Table III in the Data Supplement).
Procedural Characteristics
Procedural characteristics of TAVI patients are given in 
Table 4. Mean procedural time was 66±38 minutes. Most 
Table 5. Unadjusted and Adjusted Clinical Outcomes at 1 Year of Transcatheter Aortic Valve Implantation Patients Stratified 
According to MR Grade
Mild or Less MR Moderate or Severe MR Unadjusted Events Adjusted Events
n=52 n=61 HR or RR (95% CI) P Value HR or RR (95% CI) P Value
1-y follow-up
  All cause death, n (%) 6 (11.5) 23 (38.1) 3.85 (1.57–9.47) 0.003 3.27 (1.31–8.15) 0.011
   Cardiovascular death, n (%) 4 (7.9) 22 (36.5) 5.50 (1.89–15.97) 0.002 4.62 (1.57–13.60) 0.005
  Cerebrovascular events 3 (5.8) 4 (6.7) 1.18 (0.26–5.26) 0.83 0.78 (0.16–3.81) 0.76
   Major stroke, n (%) 2 (3.9) 2 (3.4) 0.88 (0.12–6.25) 0.90 0.27 (0.02–3.08) 0.29
  Myocardial infarction, n (%) 1 (1.9) 1 (1.7) 0.85 (0.05–13.61) 0.91 0.37 (0.02–8.06) 0.53
  All cause death or major 
stroke, n (%)
7 (13.5) 25 (41.4) 3.61 (1.56–8.36) 0.003 2.86 (1.21–6.76) 0.016
  All cause death, major stroke, 
or MI, n (%)
7 (13.5) 25 (41.4) 3.62 (1.56–8.38) 0.003 2.88 (1.22–6.81) 0.016
Depicted are counts (incidence rates % from life-tables estimate). HRs (95% CI) from Cox Regressions for time-to-event data. In case of zero events continuity correct 
RR (95% CI) with Fisher test P values are reported. Adjusted HRs (95% CI) from Cox Regressions, correcting for peripheral vascular disease and logistic Euroscore. CI 
indicates confidence interval; HR, hazard ratios; MR, mitral regurgitation; and RR, risk ratios.
Table 6. Clinical Outcomes of Patients With Low-Ejection Fraction, Low-Gradient Severe Aortic Stenosis Assigned to TAVI Versus 
Medical Therapy Stratified According to MR Grade
Medical TAVI Mild or Less MR
Moderate or 
Severe MR
Medical vs TAVI Medical vs TAVI
Mild or Less MR
Moderate or 
Severe MR Mild or Less MR
Moderate or 
Severe MR HR or RR (95% CI) P Value HR or RR (95% CI) P Value
n=19 n=20 n=52 n=61
1-y follow-up
All-cause death, 
n (%)
11 (57.9) 13 (65.7) 6 (11.5) 23 (38.1) 0.14 (0.05–0.38) <0.001 0.38 (0.19–0.75) 0.005
  Cardiovascular 
death, n (%)
10 (55.4) 13 (65.7) 4 (7.9) 22 (36.5) 0.10 (0.03–0.33) <0.001 0.36 (0.18–0.73) 0.004
Depicted are counts (incidence rates % from life-tables estimate). HRs (95% CI) from Cox Regressions for time-to-event data. CI indicates confidence interval; HR, 
hazard ratios; MR, mitral regurgitation; RR, risk ratios; and TAVI, transcatheter aortic valve implantation.
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patients underwent transfemoral TAVI under conscious seda-
tion. Mean length of hospital stay was 7.9±5.6 days. One 
patient with moderate MR undergoing transapical TAVI 
required conversion to conventional SAVR and subsequently 
died. Overall, 16.8% of patients had postprocedural ≥moder-
ate aortic regurgitation with no significant differences between 
groups (P=0.37).
Clinical Outcomes of TAVI Patients Stratified 
According to MR Grade
One-year follow-up was complete for 112 of 113 (99.1%) 
TAVI patients with 1 patient withdrawing consent for follow-
up 113 days after TAVI. Event rates with crude and adjusted 
hazard ratios (adj HR) for all major clinical end points at 30 
days and 12 months are provided in Table IV in the Data Sup-
plement and Table 5, respectively.
Six deaths occurred at 30 days of which 4 were in-hospital. 
No significant differences in all-cause mortality (3.8% ver-
sus 6.6%; P=0.52), cardiovascular death (3.8% versus 6.6%; 
P=0.52), or major adverse cardiovascular and cerebrovas-
cular events (3.8% versus 11.5%; P=0.17) were observed at 
30 days between groups. There were no significant differ-
ences in other end points at 30 days (Table IV in the Data 
Supplement).
Time-to-event curves for all-cause mortality and car-
diovascular death among all TAVI patients are shown in 
Figure 1. As compared with TAVI patients with mild or 
less MR, LEF-LG TAVI patients with moderate to severe 
MR had incidence higher rate of all-cause mortality (11.5% 
versus 38.1%; unadjusted HR, 3.85; 95% CI, 1.57–9.47; 
P=0.003), which was driven by cardiovascular death (7.9% 
versus 36.5%; unadjusted HR, 5.50; 95% CI, 1.89–15.97; 
P=0.002; Table 6). On multivariate analysis, moderate or 
severe MR was an independent predictor for all-cause mor-
tality (adj HR, 3.27; 95% CI, 1.31–8.15; P=0.011), cardiac 
death (adj HR, 4.62; 95% CI, 1.57–13.60; P=0.005) and 
major adverse cardiovascular and cerebrovascular events 
(adj HR, 2.88; 95% CI, 1.22–6.81; P=0.002) at 1 year among 
TAVI patients after adjusting for the univariate predictors of 
peripheral vascular disease and logistic EuroSCORE. Time-
to-event curves stratified according to MR cause (ie, func-
tional versus degenerative) among moderate or severe MR 
TAVI patients only are shown in Figure 2. As compared with 
functional MR, patients with degenerative MR had a higher 
rate of death (29.5% versus 61.2%; adj HR, 3.38; 95% CI, 
1.32–8.67; P=0.011) driven by cardiac death (adj HR, 2.92; 
P=0.029) at 1 year.
NYHA functional class at baseline and 1-year follow-up 
in both the TAVI groups is shown in Figure 3. At 1 year, 58 
(56.9%) patients improved, 12 (11.8%) patients had no change, 3 
(2.9%) had worsened, and 29 (28.4%) had died (χ2 test, P=0.02). 
Improvement in NYHA class of the surviving patients did not dif-
fer between moderate or severe MR (82%) as compared with sur-
viving patients with mild or less MR (76%; Fisher test, P=0.77).
Clinical Outcomes of Patients Assigned to TAVI 
Versus MT Stratified According to MR Grade
Event rates with crude HRs for all-cause mortality and car-
diovascular death at 1-year comparing patients undergoing 
TAVI versus patients assigned to MT stratified according to 
MR grade (mild or less MR versus moderate or severe MR) 
are shown in Table 6. Time-to-event curves for all-cause mor-
tality and cardiovascular death among all patients are shown 
in Figure 4. As compared with patients with mild or less MR 
undergoing MT, patients with mild or less MR undergoing 
TAVI had a significantly lower all-cause (HR, 0.14; 95% CI, 
0.05–0.38; P<0.001) and cardiovascular mortality (HR, 0.10; 
Figure 3. Functional status expressed by the New York Heart 
Association (NYHA) classification at baseline and 1-year follow-
up among low-ejection fraction, low-gradient, severe aortic ste-
nosis patients undergoing transcatheter aortic valve implantation 
stratified according to the presence of mild or less mitral regurgi-
tation (MR) and moderate or severe MR at baseline.
Figure 2. Kaplan–Meier analysis of death (A) and cardiovascular death (B) at 1 year among patients undergoing transcatheter aortic valve 
implantation (TAVI) with moderate or severe mitral regurgitation (MR) only stratified according to MR cause (functional vs degenerative).
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95% CI, 0.03–0.33; P<0.001). As compared with patients 
with moderate or severe MR undergoing MT, patients with 
moderate or severe MR undergoing TAVI had a significantly 
lower all-cause (HR, 0.38; 95% CI, 0.019–0.75; P=0.005) and 
cardiovascular (HR, 0.36; 95% CI, 0.18–0.73; P=0.004) mor-
tality at 1 year.
Echocardiographic Outcomes Among TAVI Patients
Changes in MR at baseline, discharge, and 1 year are shown 
in Figure 5. Among moderate to severe MR patients surviving 
to discharge, an acute improvement in MR was observed in 28 
(46.7%) patients, no change in 25 (41.7%) and worsened in 4 
(6.7%). Twelve patients with mild MR at baseline progressed 
to moderate MR after TAVI (Figure 4). No significant differ-
ences in overall 1 year survival rates were observed between 
patients with no change or worsening MR and patients with 
improvement of MR on discharge echo (Figure in the Data 
Supplement).
One-year echocardiographic follow-up was performed 
a median of 379 days (IQR, 262–511 days) after TAVI and 
was available in 77 of 84 (92%) surviving patients (Figure 6). 
Among moderate to severe MR patients, 19 (31.7%) patients 
improved, 16 (26.7%) patients had no change, 2 (3.3%) 
patients worsened an MR grade, and 23 (38.3%) patients had 
died at 1-year follow-up. Among mild or less MR patients, 
6 (13.0%) patients had moderate MR at 1-year follow-up, of 
whom 4 were observed to have had moderate MR at discharge.
Changes in LVEF, left ventricular end-systolic diameter 
and pulmonary artery systolic pressure among 1-year survi-
vors are shown in Figure 7. Both LVEF and pulmonary artery 
systolic pressure significantly improved at 1-year with no 
significant interaction between groups. A borderline trend 
toward a significant reduction in left ventricular end-systolic 
diameter (P=0.08) was observed at 1-year with no significant 
interaction between groups. No overall significant changes in 
LVEDD (P=0.29) or LV mass indices (P=0.91) were observed 
at 1-year and no significant interaction was observed between 
groups for either variables.
As compared with 1-year survivors who underwent TAVI, 
nonsurvivors who underwent TAVI at 1 year had significantly 
worse LVEF, significantly larger left atrial diameters and 
a significantly higher prevalence of moderate to severe MR 
(Table V in the Data Supplement).
Discussion
To the best of our knowledge, this study is the first to assess 
the effect of MR on clinical outcomes among patients with 
LEF-LG severe AS undergoing TAVI. Our main finding 
was that moderate or severe MR was a strong independent 
predictor of 1-year mortality among patients with LEF-LG 
severe AS undergoing TAVI, which was predominantly 
driven by cardiac death. Among moderate or severe MR 
patients undergoing TAVI, degenerative MR was associ-
ated with worse outcomes as compared with functional MR 
patients. We also observed that LEF-LG patients assigned 
Figure 4. Kaplan–Meier analysis of death (A) and cardiovascular death (B) at 1 year among patients with low-ejection fraction, low-gra-
dient severe aortic stenosis assigned to medical therapy vs transcatheter aortic valve implantation (TAVI) stratified according to the pres-
ence of mild or less mitral regurgitation (MR) and moderate or severe MR at baseline.
Figure 5. Changes in mitral regurgitation (MR) over time (base-
line, discharge, and 1 year) among patients with low-ejection 
fraction, low-gradient (LEF-LG) severe aortic stenosis undergo-
ing transcatheter aortic valve implantation stratified according 
to presence of mild or less MR and moderate or severe MR at 
baseline (A) and according to functional versus degenerative 
cause among LEF-LG patients with moderate to severe MR at 
baseline (B).
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to MT had a dismal prognosis, independent of MR severity 
grade, suggesting that TAVI should not be withheld from 
symptomatic patients with LEF-LG severe AS even in the 
presence of moderate to severe MR. However, the latter 
observation should be considered hypothesis generating 
owing to the fact that the MT group sample size was rela-
tively small and that patients assigned to MT were at higher 
surgical risk as compared with TAVI patients. Among TAVI 
patients, the majority of deaths occurred in the late period 
(>30 days) with no differences observed at 30 days. How-
ever, it should be noted that there were not enough events 
in the early period (<30 days) to test for a mortality differ-
ence at this stage. Immediately after TAVI, an improvement 
in MR grade was observed in almost half of the patients 
with moderate to severe MR at baseline. However, MR 
improvement did not predict 1-year survival. Among sur-
viving patients with moderate MR at 1-year (all patients 
with severe MR died), improvements in NYHA functional 
class status was associated with improvement in LVEF and 
pulmonary pressures although LV remodeling was limited 
in both the groups. Just under a third of patients (31%) 
with moderate or severe MR at baseline demonstrated an 
improvement in MR severity 1 year after TAVI.
Moderate to Severe MR in Unselected TAVI 
Candidates
Previous studies have shown that moderate to severe MR 
is present in up to one fifth of unselected patients undergo-
ing TAVI.19–22 However, the effect of moderate or severe MR 
on clinical outcomes among an unselected patient popula-
tion undergoing TAVI is controversial.23–25 In contrast to this 
study, most studies to date have been confounded by the fact 
that MR groups have been unevenly matched with moderate 
or severe MR patients undergoing TAVI having significantly 
higher baseline risk scores, poorer LV function and a higher 
prevalence of atrial fibrillation and pulmonary hypertension 
Figure 7. Changes in left ventricular ejection fraction (LVEF; A), 
pulmonary artery systolic pressure (PASP; B) and left ventricular 
end-systolic diameter (LVESD; C) over time (baseline, discharge, 
and 1-year) among patients with low-ejection fraction, low-gradi-
ent severe aortic stenosis undergoing transcatheter aortic valve 
implantation stratified according to mild or less mitral regurgita-
tion (MR) and moderate or severe MR.
Figure 6. Tracked outcomes of individual patients with low-
ejection fraction, low-gradient severe aortic stenosis undergoing 
transcatheter aortic valve implantation over time (baseline, dis-
charge, and 1 year) according to mitral regurgitation (MR) grade 
or death at follow-up, stratified according to mild or less MR (A) 
or moderate or severe MR (B). Two patients (1 in each group) 
were missing discharge echocardiograms and 7 patients were 
missing 1-year follow-up echocardiograms (6 in mild or less MR 
group and 1 in moderate or severe MR group). Baseline to dis-
charge: P<0.001; of survivors at discharge: P<0.001. Discharge 
to 1-year follow-up P=0.006; of survivors at 1 year: P=0.11.
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as compared with patients with mild or less MR.23–25 Togg-
weiler et al24 reported that moderate to severe MR was asso-
ciated with a higher 30 days, but not late, mortality among 
unselected patients undergoing TAVI with a balloon expand-
able valves. They also found that improvement in MR was 
predicted by high gradients, functional MR, absence of pul-
monary hypertension, and absence of atrial fibrillation. In 
the Placement of Aortic Transcatheter Valves (PARTNER) 
A trial, Barbanti et al23 reported no significant differences 
in overall 2-year mortality among patients with moderate 
to severe MR undergoing TAVI as compared with patients 
with mild or less MR. Conversely, moderate or severe MR 
at baseline was associated with a significantly higher 2-year 
mortality rate among SAVR patients.23 A study from a large 
(n=1007) multicentre Italian registry reported that moderate 
and severe MR was associated with significantly higher mor-
tality rates both at 30 days and 1 year as compared with mild 
or less MR in patients undergoing TAVI with a self-expand-
ing device.25 However, both the moderate and the severe MR 
groups had significantly higher baseline risk scores, higher 
pulmonary pressures, and a prevalence of atrial fibrillation as 
compared with mild or less MR groups.25
MR in Patients With Low-Ejection Fraction, Low-
Gradient Severe AS Undergoing TAVI
In most studies to date, the prevalence of moderate or severe 
MR is higher among patients with LEF-LG as compared with 
high-gradient severe AS patients (Figure 8). LEF-LG patients 
have dilated LV cavities, which can lead to annular dilatation 
and reduce or eliminate normal coaptation between the ante-
rior and the posterior mitral valve leaflets resulting in MR.33 
Most patients had dilated LV cavities in this study (Table 2).
We observed that LEF-LG patients with moderate or severe 
MR undergoing TAVI had a markedly higher 1-year mortal-
ity rates as compared with similar patients presenting with 
mild or less MR after TAVI. Furthermore, mortality was 3 
times higher with degenerative as compared with functional 
MR among moderate or severe MR TAVI patients. The data 
shown in Figure 3 might be interpreted as showing that 
TAVI in LEF-LG patients with moderate or severe MR is a 
high risk/reward proposition. It seems that most patients are 
either dead or greatly improved at 1 year after the procedure. 
The data shown in Figure 6 show the dynamic nature of MR 
after TAVI. The reason why MR changes between the early 
and late time points may relate to the cause of MR. Whereas 
functional MR may be expected to improve over time after 
TAVI, degenerative MR would not since the primary pathol-
ogy is because of intrinsic abnormalities of the mitral valve 
apparatus.33 The reasons for the observed higher mortality 
rate with significant MR are unclear. MR is a known cause 
of pulmonary hypertension, which is an independent predic-
tor of mortality after TAVI.20 Pulmonary artery pressures were 
significantly higher among moderate or severe MR patients on 
right heart catheterization. Furthermore, pulmonary hyperten-
sion was predominantly postcapillary suggesting a left heart 
cause. The added burden of moderate or severe MR may lead 
to a worse severity of PH, which may translate into the higher 
mortality rates observed. An alternative hypothesis may relate 
to the fact that patients with moderate or severe MR may have 
a more severe underlying myocardial disease resulting in 
lower contractile reserve, which may be multifactorial such 
as an end-stage manifestation of AS or influence of other fac-
tors, such as arterial hypertension, aging, and fibrosis. It is 
also possible that moderate or severe MR may reduce forward 
stroke volume and, thereby contribute to pseudostenosis and 
thus patients who undergo TAVI may not experience as much 
of a benefit from TAVI. However, this would not be expected 
to account for the higher mortality observed in the moderate 
to severe MR group.
Clinical Implications
This study has clinical implications about patient selection and 
the management of patients presenting with LEF-LG severe 
AS. First, TAVI can be safely performed in LEF-LG patients 
regardless of MR severity because no differences periproce-
dural or 30-day outcomes were observed. However, because 
of the poor medium term outlook among LEF-LG patients 
with even moderate MR, the question remains as to whether 
it should be done on everybody. Although overall and cardiac 
mortality rates observed among LEF-LG patients with mod-
erate or severe MR in this study (38.1% and 36.5%, respec-
tively) were lower than that observed in the medical cohort of 
the PARTNER B trial (49.7% and 41.9%, respectively), this 
study does raise questions about futility in this patient subset.22 
However, we observed that LEF-LG patients with moderate or 
severe MR assigned to MT during the same treatment period at 
Figure 8. Comparison of the prevalence of moder-
ate or severe mitral regurgitation between patients 
with low-ejection fraction, low-gradient (LEF-LG) 
and high-gradient (HG) severe aortic stenosis in 
studies assessing patients undergoing transcath-
eter aortic valve implantation. *In Herrmann et al,7 
the comparison was between low-flow and normal 
flow only irrespective of the mean gradient or left 
ventricular ejection fraction.
 at Universitaetsbibliothek Bern on February 19, 2015http://circinterventions.ahajournals.org/Downloaded from 
12  O’Sullivan et al  TAVI, Low Gradient Aortic Stenosis, and Mitral Regurgitation
our institution had significantly worse outcomes as compared 
with LEF-LG patients with moderate or severe MR assigned 
to TAVI (Figure 4; Table 6). These results suggest that it is not 
futile to treat patients with LEF-LG severe AS and concomi-
tant moderate or severe MR with TAVI. With the advent of 
novel percutaneous methods for the treatment of MR in high-
risk patients (eg, MitraClip), it remains to be seen whether such 
procedures combined with TAVI may improve clinical out-
comes among LEF-LG patients with moderate or severe MR.34
Limitations
First, this is a single-center observational study and may con-
tain bias. However, our best knowledge, this is the first study to 
report the effect of moderate to severe MR on clinical outcomes 
among patients with LEF-LG undergoing TAVI. Data were pro-
spectively collected and all events were independently adjudi-
cated by a clinical events committee. Second, this was a selective 
patient population and, therefore, the number of patients included 
in the study was relatively small. However, our numbers favor-
ably compare with previous studies focusing on LEF-LG and 
SAVR and TAVI.10,14,15 Third, dobutamine stress echocardiogra-
phy was only performed on a third of patients undergoing TAVI 
included in this study. Fourth, given that there were more deaths 
in the moderate to severe MR among TAVI patients, the results 
of the analyses on the echocardiographic parameters baseline, 
discharge, and at 1 year among TAVI patients are affected by 
this. Because the deaths could be interpreted as cases of miss-
ing data, their exclusion can affect the results of the analyses, 
especially because these observations are not missing at random. 
This could, therefore, introduce an unmeasured bias. Finally, 
the sample size of the MT control group was relatively small 
and precluded propensity score or inverse probability treatment 
weighting analysis between MT and TAVI groups. In addition, 
MT patients were higher risk as compared with TAVI patients.
Conclusions
Moderate or severe MR is a strong independent predictor of 
1-year mortality among patients with LEF-LG undergoing 
TAVI. Degenerative MR predicts a worse outcome among 
moderate or severe MR patients. LEF-LG patients assigned 
to MT have a dismal prognosis independent of MR severity 
suggesting that TAVI should not be withheld from patients 
with LEF-LG severe AS even in the presence of concomitant 
moderate or severe MR.
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